In summary, our research identified that EGFR L858R neoantigen had the potential to generate cancer vaccines in NSCLC patients with HLA A*33:03 and revealed the possible underlying immunological features between EGFR mutant subtypes. Here, EGFR is linked to non-small cell lung carcinoma.